Cytokinetics (CYTK) Accumulated Expenses (2010 - 2026)

Cytokinetics (CYTK) has reported Accumulated Expenses for 17 consecutive years, with $27.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 36.91% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (down 36.91% YoY), while the FY2025 annual figure was $45.2 million, up 28.52% from the prior year.
• Accumulated Expenses eased to $27.4 million in Q1 2026 per CYTK's latest filing, from $45.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $52.3 million in Q2 2025 and bottomed at $12.5 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $31.7 million across 5 years, with a median of $31.5 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 321.88% — and 2023, when it tumbled 53.68%.
• Cytokinetics' Accumulated Expenses stood at $21.8 million in 2022, then surged by 95.9% to $42.6 million in 2023, then fell by 17.61% to $35.1 million in 2024, then increased by 28.52% to $45.2 million in 2025, then tumbled by 39.41% to $27.4 million in 2026.
• Business Quant data shows CYTK's Accumulated Expenses at $27.4 million in Q1 2026, $45.2 million in Q4 2025, and $33.2 million in Q3 2025.